What is RNA and how can we use the body's own RNA editing machinery to treat disease? Learn more about the Axiomer® RNA editing technology and how we are creating a new class of medicines.
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
… am extremely passionate about ProQR’s focus on developing RNA technologies that allow us to develop potentially … its strategy of accelerating our next-generation RNA-base editing platform technology, Axiomer ® . I am in the unique … yield a new class of medicines. Our proprietary Axiomer ® RNA-editing technology enables your body to treat disease, …
Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
